Have Questions? Email support@soracilabs.com
Kisspeptin: A Metastasis Suppressor That Turned Out to Run Puberty
Kisspeptin was found as a tumour metastasis suppressor and only later identified as the upstream regulator of GnRH release. Origins, nomenclature, KISS1R pharmacology and why kisspeptin-10 works.
Kisspeptin has one of the stranger origin stories in peptide biology. It was discovered as a tumour metastasis suppressor, named after a chocolate bar, and only later turned out to be the master switch for mammalian reproduction. Both findings are real, and the gap between them is what makes the peptide worth understanding properly rather than by slogan.
The short version
- The KISS1 gene was identified as a metastasis suppressor in a human malignant melanoma line. Its longest product, kisspeptin 68–121, was named metastin for that reason.
- Its receptor is KISS1R, formerly the orphan receptor GPR54, a rhodopsin-family GPCR that stayed orphaned until 2001.
- In 2003 two groups independently found that loss-of-function mutations in KISS1R cause idiopathic hypogonadotropic hypogonadism — the reproductive role arrived a decade after the cancer one.
- Kisspeptin-10 is a C-terminal fragment. Shorter C-terminal fragments show affinities and efficacies comparable to the full-length peptide.
Two discoveries, ten years apart
In the mid-1990s, work on metastasis suppression in a human malignant melanoma cell line turned up a gene whose expression suppressed metastatic spread. It was named KISS1, and the longest peptide product of the gene — residues 68–121 of the precursor protein — was called metastin. At that point the peptide had nothing to do with reproduction as far as anyone knew.
Separately, a rhodopsin-family G-protein-coupled receptor called GPR54 sat in the deorphanisation queue with no known ligand. In 2001 it was matched to the KISS1 gene products, which turned an oncology finding and a receptor-pharmacology finding into the same story.
The reproductive role arrived in 2003, from two groups at once. De Roux and colleagues, publishing in PNAS, and Seminara and colleagues, publishing in the New England Journal of Medicine, independently identified loss-of-function mutations in the receptor in patients with idiopathic hypogonadotropic hypogonadism. Kiss1r knockout mice reproduced the phenotype. A receptor whose ligand had been characterised as a metastasis suppressor turned out to be required for puberty.
Where kisspeptin sits in the reproductive axis
The hypothalamic–pituitary–gonadal axis is conventionally drawn as GnRH → LH/FSH → gonadal steroids. Kisspeptin sits upstream of that, on the GnRH neurons themselves.
The functional consequence is that kisspeptin signalling is upstream of everything downstream of GnRH. That is why a receptor mutation produces hypogonadotropic hypogonadism rather than a subtler phenotype: without the input, the pulse generator does not run.
The hypothalamic population most often discussed in this context sits in the arcuate nucleus and co-expresses kisspeptin, neurokinin B and dynorphin — the KNDy population, named for those three. The working model is that neurokinin B provides the excitatory drive and dynorphin the inhibitory brake, and that the interplay between them generates the pulsatile output that kisspeptin then delivers to GnRH neurons.
Kisspeptin-10 and why the fragment works
The KISS1 precursor is processed into several peptides of different lengths, all sharing the same C-terminus: kisspeptin-54 (metastin), and shorter forms including kisspeptin-14, kisspeptin-13 and kisspeptin-10. All of them terminate in the same amidated C-terminal decapeptide sequence.
That shared C-terminus is the receptor-binding region, which is why the short fragments show affinities and efficacies comparable to the full-length peptide at KISS1R. Kisspeptin-10 is the commonly used research form for the same reason short fragments are preferred elsewhere: it is cheaper to synthesise, easier to characterise, and carries the pharmacophore.
Where the fragment and the full peptide diverge
Comparable receptor activity does not mean comparable behaviour in every assay. The longer forms differ in clearance and in their interactions outside KISS1R, and the metastasis-suppression literature was built on the longer species. If your experiment concerns receptor pharmacology, the fragment is appropriate. If it concerns the oncology findings, check which species the source paper actually used before substituting.
Nomenclature you will meet in the literature
| Term | What it refers to |
|---|---|
| KISS1 | The gene, identified as a metastasis suppressor |
| Metastin | Kisspeptin-54, the longest processed product (residues 68–121) |
| Kisspeptin-10 | C-terminal decapeptide fragment; the common research form |
| KISS1R | The receptor, current nomenclature |
| GPR54 | The same receptor, former name — still widespread in pre-2010 papers |
| AXOR12 / hOT7T175 | Additional legacy names for the same receptor |
| KNDy neurons | Arcuate neurons co-expressing kisspeptin, neurokinin B and dynorphin |
The multiplicity of names is a genuine obstacle when searching the literature. A query for “kisspeptin” alone will miss a substantial body of receptor work published under GPR54.
Handling kisspeptin in the laboratory
- Supplied lyophilised. Store at −20 °C, protected from light, until reconstituted.
- Kisspeptin-10 carries an amidated C-terminus; that amide is part of the active pharmacophore, and hydrolysis of it is a degradation route worth considering when solutions are held for long periods.
- Reconstitute with bacteriostatic water where the vial will be entered more than once.
- Add diluent down the vial wall, swirl gently, never shake.
- Date the vial, aliquot once, and avoid freeze–thaw cycling.
Full protocol in the peptide reconstitution guide.
Kisspeptin: frequently asked questions
Why is it called kisspeptin?
From the KISS1 gene name, which was assigned by the group that identified it as a metastasis suppressor in Hershey, Pennsylvania — a nod to the town’s best-known product. The “-in” suffix follows peptide convention.
Are kisspeptin and metastin the same thing?
Metastin is kisspeptin-54, the longest processed product of the KISS1 precursor. Kisspeptin is the family name covering that and the shorter C-terminal fragments.
Is GPR54 a different receptor from KISS1R?
No. Same receptor, older name. You will also see AXOR12 and hOT7T175 in the deorphanisation-era literature.
Why does kisspeptin-10 work if it is only part of the molecule?
Because the receptor-binding region is the shared C-terminus, which every processed form carries. Shorter fragments show comparable affinity and efficacy at KISS1R.
What did the 2003 mutation findings actually establish?
That KISS1R signalling is required for normal reproductive development. Loss-of-function mutations produce idiopathic hypogonadotropic hypogonadism in humans, and the receptor knockout reproduces it in mice.
Related products
Kisspeptin 10mgLyophilised kisspeptin-10. Research use only.View product →OxytocinNonapeptide, neurohypophysial hormone. Research use only.View product →Hospira Bacteriostatic Water 30mlPreserved diluent for multi-withdrawal vials.View product →
References
The primary literature below is indexed on PubMed, and compound records are held at PubChem.
- Kisspeptin and KISS1R: a critical pathway in the reproductive system. Review covering KISS1 identification as a metastasis suppressor, receptor deorphanisation in 2001, and the 2003 mutation findings.
- de Roux N, et al. Loss-of-function mutations of the GPR54 gene in idiopathic hypogonadotropic hypogonadism. PNAS, 2003.
- Seminara SB, et al. The GPR54 gene as a regulator of puberty. New England Journal of Medicine, 2003.
- Reviews of Kiss1 neurons as integrators of endocrine, metabolic and environmental input to the hypothalamic–pituitary–gonadal axis.
Research use only. All products sold by Soraci Labs are intended strictly for in-vitro laboratory research and are not for human or veterinary use, ingestion, injection, or any form of clinical application. Nothing on this page is medical advice or a claim of therapeutic benefit. This article summarises published preclinical literature for educational purposes only.